Interestingly, membranous and cytoplasmic EPHB2 were negatively correlated indicating opposite patient prognosis: cytoplasmic EPHB2 accounted for shorter breast cancer survival and membranous EPHB2 for good prognosis. This evidence concerns the gene EPHB2 and breast carcinoma.